Effect of Human Umbilical Cord-derived Mesenchymal Stem Cells on Non-cardiac Surgery-induced Lung Injury

Launched by SHANGHAI EAST HOSPITAL · Aug 2, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the effects of special cells derived from human umbilical cords, called mesenchymal stem cells, on patients who have lung injuries caused by non-cardiac surgery. The goal is to see if these cells can help improve lung function and make breathing easier, especially for individuals who have ischemic heart disease, a condition that affects the heart's blood supply. The trial is currently looking for participants who are undergoing their first knee replacement surgery and are between the ages of 21 and 92.

If you join the study, you will receive treatment with these stem cells and be monitored for any changes in your lung function and overall symptoms. You will also be checked for any side effects from the treatment. To participate, you need to meet specific health criteria, like having certain heart conditions, and you must be able to provide informed consent. It's important to note that there are some exclusions, such as having serious health issues or infections, being pregnant, or having had a recent stroke. Overall, this study aims to explore a potentially new way to help patients recover after surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The electrocardiogram showed T wave change and ST segment depression
• • New York Heart Association (NYHA) Classification of cardiac function Ⅰ-Ⅱ level
• • The patient who first time to receive knee replacement
• • General anesthesia lasted about 2h
• • Signed informed consent
• Exclusion Criteria:
• • Does not meet the above selection criteria
• • Unable to sign the informed consent
• • Patients with a malignant tumor, other serious systemic diseases, or psychosis
• • Pregnancy, lactation, and those who are not pregnant but do not take effective contraceptives measures
• • The patient with a history of an allergic reaction to biological products or drug
• • The patient has any infectious diseases (including bacterial and viral infections)
• • The patient with cardiac pacemaker implantation within 3 months prior to enrollment
• • The patient who had a stroke within 6 months prior to enrollment
• • Unable to comply with the agreed timetable of this study
• • Patients who are participating in other clinical trials
• • Others who are clinically considered unsuitable for this treatment.